trending Market Intelligence /marketintelligence/en/news-insights/trending/te4xu-8hs3h4fzxfrlonma2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Johnson & Johnson seeks additional Japanese approval for multiple myeloma drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Johnson & Johnson seeks additional Japanese approval for multiple myeloma drug

Johnson & Johnson submitted a supplemental new drug application in Japan for Darzalex in front-line multiple myeloma.

Multiple myeloma is an incurable blood cancer that forms in plasma cells which are responsible for producing antibodies.

J&J unit Janssen Pharmaceutical KK submitted an application to Japan's Ministry of Health, Labor and Welfare seeking approval for Darzalex, combined with Takeda Pharmaceutical Co. Ltd.'s Velcade, Aspen Pharmacare Holdings Ltd.'s Alkeran and prednisone, for treating newly diagnosed multiple myeloma patients who are not eligible for autologous stem cell transplant. The application will be placed on priority review by the regulator.

The application is based on data from a 706-patient phase 3 trial, called Alcyone, which showed the Darzalex regimen reduced the risk of the disease getting worse or death by 50% in certain multiple myeloma patients. The Japanese regulator also gave Darzalex its orphan drug designation as a therapy for newly diagnosed multiple myeloma.

Darzalex was licensed by New Brunswick, N.J.-based Johnson & Johnson from Copenhagen-based Genmab A/S in 2012, and is approved in the U.S. and EU as a therapy for multiple myeloma.

Darzalex is already approved in Japan, for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, to treat adults with multiple myeloma that has recurred or has not responded to treatment.